{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:52:37Z","timestamp":1785840757050,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41409-026-02918-w","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:42:26Z","timestamp":1781923346000},"page":"1083-1090","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time to resolution of veno-occlusive disease\/sinusoidal obstruction syndrome post-HCT in defibrotide-treated adults from two European registries"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vian","family":"Amber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Petitprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalina","family":"Dronamraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-9592","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"2918_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2023;58:749\u201354. https:\/\/doi.org\/10.1038\/s41409-023-01992-8.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157\u201368. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.024.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2918_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transpl. 2020;55:485\u201395. https:\/\/doi.org\/10.1038\/s41409-019-0705-z.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41409-023-02077-2","volume":"58","author":"T Ruutu","year":"2023","unstructured":"Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kr\u00f6ger N, et al. Current incidence, severity, and management of veno-occlusive disease\/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study. Bone Marrow Transpl. 2023;58:1209\u201314. https:\/\/doi.org\/10.1038\/s41409-023-02077-2.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bbmt.2018.07.039","volume":"25","author":"LE Roeker","year":"2019","unstructured":"Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, et al. Early clinical predictors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after myeloablative stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:137\u201344. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.039.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2918_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, D\u00edaz-Bey\u00e1 M, Rosi\u00f1ol L, Mart\u00ednez C, Fern\u00e1ndez-Avil\u00e9s F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl. 2011;17:1713\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2011.06.006.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2918_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578\u201382. https:\/\/doi.org\/10.1182\/blood-2003-01-0255.","journal-title":"Blood"},{"key":"2918_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375:740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"key":"2918_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bbmt.2010.11.019","volume":"17","author":"M Palomo","year":"2011","unstructured":"Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2011;17:497\u2013506. https:\/\/doi.org\/10.1016\/j.bbmt.2010.11.019.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2918_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2015;50:781\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.52.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR11","unstructured":"Defitelio\u00ae (80 mg\/mL concentrate for solution for infusion) summary of product characteristics. European Medicines Agency: Jazz Pharmaceuticals Ireland Limited.; 2023."},{"key":"2918_CR12","unstructured":"DEFITELIO\u00ae (defibrotide sodium) injection, for intravenous use [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc, 2025."},{"key":"2918_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41409-022-01900-6","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Blaise D, Peffault de Latour R, Labopin M, Bourhis JH, Bruno B, et al. Real-world use of defibrotide for veno-occlusive disease\/sinusoidal obstruction syndrome: the DEFIFrance Registry Study. Bone Marrow Transpl. 2023;58:367\u201376. https:\/\/doi.org\/10.1038\/s41409-022-01900-6.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR14","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41409-021-01265-2","volume":"56","author":"M Mohty","year":"2021","unstructured":"Mohty M, Battista ML, Blaise D, Calore E, Cesaro S, Maximova N, et al. A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease\/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study. Bone Marrow Transpl. 2021;56:2454\u201363. https:\/\/doi.org\/10.1038\/s41409-021-01265-2.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society For Blood and Marrow Transplantation. Bone Marrow Transpl. 2018;53:138\u201345. https:\/\/doi.org\/10.1038\/bmt.2017.161.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2016;51:906\u201312. https:\/\/doi.org\/10.1038\/bmt.2016.130.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2020-136670","volume":"136","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Faraci M, Yakoub-Agha I, Girault S, Wheeler K, Ryan RJ, et al. Treatment duration, symptom resolution, and survival in defibrotide-treated patients with veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic cell transplantation: analysis of a multinational, prospective, observational registry study. Blood. 2020;136:32\u201333. https:\/\/doi.org\/10.1182\/blood-2020-136670.","journal-title":"Blood"},{"key":"2918_CR18","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656\u201365. https:\/\/doi.org\/10.1182\/blood-2015-10-676924.","journal-title":"Blood"},{"key":"2918_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41409-023-02177-z","volume":"59","author":"RD Baggett","year":"2024","unstructured":"Baggett RD, Gatwood KS. Clinical outcomes of early defibrotide discontinuation: a single-center case series. Bone Marrow Transpl. 2024;59:285\u20137. https:\/\/doi.org\/10.1038\/s41409-023-02177-z.","journal-title":"Bone Marrow Transpl"},{"key":"2918_CR20","doi-asserted-by":"publisher","first-page":"S500","DOI":"10.1016\/j.jtct.2025.01.795","volume":"31","author":"J Cooper","year":"2025","unstructured":"Cooper J, Parmenter S, McGinn B. Early defibrotide discontinuation in pediatric VOD\/SOS: a single-center case series. Transpl Cell Ther. 2025;31:S500. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.795.","journal-title":"Transpl Cell Ther"},{"key":"2918_CR21","doi-asserted-by":"publisher","first-page":"88.e81","DOI":"10.1016\/j.bbmt.2020.09.008","volume":"27","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Smith AR, Kernan NA, Lehmann L, Ryan RJ, Grupp SA. Analysis of time to complete response after defibrotide initiation in patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic cell transplantation. Transpl Cell Ther. 2021;27:88.e81\u201388.e86. https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.008.","journal-title":"Transpl Cell Ther"},{"key":"2918_CR22","doi-asserted-by":"publisher","unstructured":"Jiang S, Penack O, Terzer T, Schult D, Majer-Lauterbach J, Radujkovic A, et al. Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. Haematol. 2021;106:446\u201353. https:\/\/doi.org\/10.3324\/haematol.2019.238790. e-pub ahead of print.","DOI":"10.3324\/haematol.2019.238790"},{"key":"2918_CR23","doi-asserted-by":"publisher","unstructured":"Putta S, Young BA, Levine JE, Reshef R, Nakamura R, Strouse C, et al. Prognostic biomarkers for hepatic veno-occlusive disease\/sinusoidal obstruction syndrome in myeloablative allogeneic hematopoietic cell transplantation: results from the blood and marrow transplant clinical trials network 1202 study. Transpl. Cell Ther. 2023;29:166.e1\u2013166.e10. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.024.","DOI":"10.1016\/j.jtct.2022.11.024"},{"key":"2918_CR24","doi-asserted-by":"publisher","unstructured":"Shiratori S, Okada K, Sugita J, Nishida M, Iwai T, Ota S, et al. HokUS-10 scoring system predicts the treatment outcome for sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Sci. Rep. 2023;13:17374. https:\/\/doi.org\/10.1038\/s41598-023-43806-3.","DOI":"10.1038\/s41598-023-43806-3"},{"key":"2918_CR25","doi-asserted-by":"publisher","unstructured":"Putta S, Young B, Pine P, Shi J, Amber V, Saber W, et al. Verification of the Prediction Accuracy of a Biomarker-Based Prognostic for Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome (VOD\/SOS) After Hematopoietic Cell Transplantation (HCT). Transpl. Cell Ther. 2024;30:986.e1\u2013986.e7. https:\/\/doi.org\/10.1016\/j.jtct.2024.07.010.","DOI":"10.1016\/j.jtct.2024.07.010"},{"key":"2918_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol. 2018;181:816\u201327. https:\/\/doi.org\/10.1111\/bjh.15267.","journal-title":"Br J Haematol"},{"key":"2918_CR27","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","volume":"22","author":"S Corbacioglu","year":"2016","unstructured":"Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biol Blood Marrow Transpl. 2016;22:1874\u201382. https:\/\/doi.org\/10.1016\/j.bbmt.2016.07.001.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02918-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02918-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02918-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:36:43Z","timestamp":1785839803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02918-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2918"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02918-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM is one of the Editors-in-Chief at\n                      Bone Marrow Transplantation\n                      and has received research funding and honoraria from Jazz Pharmaceuticals. RPdL, ML, and DB have received honoraria from Jazz Pharmaceuticals. VA, AP, DG, and ND are employees of Jazz Pharmaceuticals and hold stock and\/or stock options in Jazz Pharmaceuticals. HL-W has nothing to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The DEFIFrance study was conducted in compliance with the ethical principles defined in the Declaration of Helsinki and according to Good Epidemiological Practice defined by ADELF (Association Des Epid\u00e9miologistes de Langue Fran\u00e7aise\u2014Association of French-language Epidemiologists) and current legislation. Written informed consent was obtained from the patient or the patient\u2019s legal guardian. Data from deceased patients were included if the patient did not express opposition to the collection of their data while they were alive. The EBMT PASS study was conducted in compliance with Good Epidemiology Practice guidelines, principles of the Declaration of Helsinki and current local regulations. All patients provided written informed consent for personal and medical data collection.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"MM is one of the Editors-in-Chief at\n                      Bone Marrow Transplantation\n                      and has received research funding and honoraria from Jazz Pharmaceuticals. RPdL, ML, and DB have received honoraria from Jazz Pharmaceuticals. VA, AP, DG, and ND are employees of Jazz Pharmaceuticals and hold stock and\/or stock options in Jazz Pharmaceuticals. HL-W has nothing to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}